New hope for lung cancer patients with no PD-L1 marker
NCT ID NCT05690945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug called QL1706, combined with chemotherapy, works better than another drug (tislelizumab) plus chemo for people with advanced non-small cell lung cancer that lacks the PD-L1 protein. About 606 adults aged 18-75 are taking part. The goal is to see if the new combo helps people live longer and controls the cancer better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?